Pharmacotherapy of benign prostatic hyperplasia: Inhibitor of 5 alpha- reductase

被引：5

作者：

Polat Ö. ^{[1
]}

Özbey I. ^{[1
]}

Gül O. ^{[1
]}

Demirel A. ^{[1
]}

Bayraktar Y. ^{[1
]}

机构：

[1] Department of Urology, Atatürk Univ. Sch. of Medicine, Research Hospital, Erzurum

来源：

International Urology and Nephrology | 1997年 / 29卷 / 3期

关键词：

Benign Prostatic Hyperplasia; Finasteride; Prostatic Volume; Residual Volume; International Urology;

D O I：

10.1007/BF02550930

中图分类号：

学科分类号：

摘要：

We studied the effects of 5 alpha-reductase inhibitor (finasteride) in the treatment of benign prostatic hyperplasia (BPH). This study is a randomized controlled trial. Sixty-two patients were treated with 5 alpha- reductase (finasteride 5 mg/day) and 61 patients (control group) with placebo for one year. Prostatic volume, maximal urine flow rate, AUA symptom scoring, residual urine volume and prostate-specific antigen (PSA) levels were evaluated at 3, 6, 9 and 12 months. In the lust 6 months prostatic volume decreased rapidly (20.5%), in the second 6 months it decreased slowly and reached the maximal rate (23.3%). Maximal urine flow rate increased in the second 6 months. AUA symptom scores decreased first at 3 months and were 4.6 points lower at the end of the 12th month. There were no significant changes in residual volume. The 5 alpha-reductase inhibitor caused a 50% decrease in PSA levels, like in other studies. Because of the prolonged use of the drug, treatment with 5 alpha-reductase inhibitor is not tolerated by many patients and being expansive its future in the pharmacotherapy of BPH is unclear.

引用

页码：323 / 330

页数：7

共 50 条

[41] Berberine Improves Benign Prostatic Hyperplasia via Suppression of 5 Alpha Reductase and Extracellular Signal-Regulated Kinase in Vivo and in Vitro [J].

Youn, Dong-Hyun ;

Park, Jinbong ;

Kim, Hye-Lin ;

Jung, Yunu ;

Kang, JongWook ;

Lim, Seona ;

Song, Gahee ;

Kwak, Hyun Jeong ;

Um, Jae-Young .

FRONTIERS IN PHARMACOLOGY, 2018, 9

[42] Efficacy and tolerability of the dual 5α-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men [J].

Roehrborn, C. G. ;

Ray, P. .

PROSTATE CANCER AND PROSTATIC DISEASES, 2006, 9 (04) :432-438

[43] Effect of the dual 5α-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia [J].

Hong, Sung Kyu ;

Min, Gyeong Eun ;

Ha, Seung Bum ;

Doo, Seung Hwan ;

Kang, Min Yong ;

Park, Hong Joo ;

Yoon, Cheol Yong ;

Jeong, Seong Jin ;

Byun, Seok-Soo ;

Lee, Sang Eun .

BJU INTERNATIONAL, 2010, 105 (07) :970-974

[44] Efficacy and tolerability of the dual 5α-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men [J].

C G Roehrborn ;

P Ray .

Prostate Cancer and Prostatic Diseases, 2006, 9 :432-438

[45] The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality [J].

Wallner, Lauren P. ;

DiBello, Julia R. ;

Li, Bonnie H. ;

Van den Eeden, Stephen K. ;

Weinmann, Sheila ;

Ritzwoller, Debra P. ;

Abell, Jill E. ;

D'Agostino, Ralph, Jr. ;

Loo, Ronald K. ;

Aaronson, David S. ;

Horwitz, Ralph, I ;

Jacobsen, Steven J. .

UROLOGY, 2018, 119 :70-78

[46] Benign Prostatic Hyperplasia [J].

Langan, Robert C. .

PRIMARY CARE, 2019, 46 (02) :223-+

[47] Early Symptom Improvement and Discontinuation of 5-α-Reductase Inhibitor (5ARI) Therapy in Patients With Benign Prostatic Hyperplasia (BPH) [J].

Kruep, Eric J. ;

Phillips, Emily ;

Hogue, Susan ;

Eaddy, Michael .

ANNALS OF PHARMACOTHERAPY, 2014, 48 (03) :343-348

[48] The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs). [J].

Ayodele, Olulade ;

Cabral, Howard J. ;

McManus, David ;

Jick, Susan .

CLINICAL EPIDEMIOLOGY, 2021, 13 :661-673

[49] Dihydrotestosterone and the prostate:: the scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia [J].

Andriole, G ;

Bruchovsky, N ;

Chung, LWK ;

Matsumoto, AM ;

Rittmaster, R ;

Roehrborn, C ;

Russell, D ;

Tindall, D .

JOURNAL OF UROLOGY, 2004, 172 (04) :1399-1403

[50] 5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer [J].

David Robinson ;

Hans Garmo ;

Lars Holmberg ;

Pär Stattin .

Cancer Causes & Control, 2015, 26 :1289-1297

← 1 2 3 4 5 →